Clopixol depot, 200 mg/ml 1 ml

Clopixol Depot is an antipsychotic (neuroleptic), a thioxanthene derivative. Clopixol has a pronounced antipsychotic and specific inhibitory effect. Clopixol may also have a transient, dose-dependent sedative effect, the rapid development of which at the beginning of therapy (before the onset of antipsychotic action) is an advantage in the treatment of acute and subacute psychosis. Tolerance to the nonspecific sedative effect of the drug occurs quickly.

The drug is especially indicated for agitation, anxiety, hostility, or aggressiveness due to its specific inhibitory effect.

A single injection of Clopixol-Acufase provides a pronounced and rapid relief of psychotic symptoms. The duration of the antipsychotic effect of the drug after one injection is 2-3 days.

The nonspecific sedative effect is seen after 2 h, reaches a maximum after about 8 h, after that it is significantly reduced and is weak with repeated injections.

The therapeutic effect of Clopixol depot is significantly more prolonged compared to Clopixol. This allows for confidence in continuous antipsychotic treatment with Clopixol Depot, which is especially important for patients who do not follow physician’s orders.

Clopixol depot prevents the development of frequent relapses associated with patients arbitrarily interrupting oral medications.

Indications

Acute and chronic schizophrenia and other psychotic disorders, especially with hallucinations, paranoid delusions and thought disorders;

States of agitation, increased anxiety, hostility, aggressiveness.

Active ingredient

Composition

How to take, the dosage

The drug is administered as a deep intramuscular injection into the upper outer quadrant of the gluteal region.

The dose and interval between injections are determined individually depending on the patient’s condition.

Clopixol depot (200 mg/ml) in maintenance treatment is administered in doses of 200-400 mg (1-2 ml) every 2-4 weeks. In some cases, higher doses or shorter injection intervals may be necessary.

Transition from oral Clopixol to intramuscular administration of Clopixol depot

The sulfa dosage is a very low dose./p>

The daily dose (mg) of Clopixol for oral administration x 8 = the dose (mg) of Clopixol Depot for intramuscular administration once every 2 weeks. Oral Clopixol should be continued for the first week after the first injection, but at a reduced dose.

Transition from intramuscular administration of Clopixol Acufase to intramuscular administration of Clopixol Depo

Single injection of Clopixol Depo./p>

Simultaneously with the final injection of Clopixol Acufase (100 mg), 200-400 mg (1-2 ml) of Clopixol Depot (200 mg/mL) should be given. Repeat injections of Clopixol depot every 2 weeks. If necessary, the drug may be used in higher doses or reduced intervals between injections.

Clopixol-Acufase and Clopixol Depot can be mixed in the same syringe and administered as one combined injection.

The subsequent doses of Clopixol depot and the intervals between injections should be set according to the patient’s condition.

Interaction

In concomitant use Clopixol may increase the sedative effect of ethanol, barbiturates and other CNS-depressant drugs.

Clopixol should not be used concomitantly with guanethidine and agents with similar effects (because neuroleptics may block their hypotensive effects).

In concomitant use, Clopixol may decrease the effectiveness of levodopa and other adrenergic agents.

Concomitant use of Clopixol with metoclopramide and piperazinem increases the risk of extrapyramidal symptoms.

Pharmaceutical incompatibility has not been established.

Special Instructions

Malignant neuroleptic syndrome (MNS) is a rare but possible fatal complication of neuroleptic use.

The main symptoms of MNS are hyperthermia, muscle rigidity and impaired consciousness combined with autonomic nervous system dysfunction (labile blood pressure, tachycardia, increased sweating).

In addition to immediate discontinuation of neuroleptics, the use of general supportive measures and symptomatic treatment is essential.

In long-term therapy, especially at high doses, careful monitoring is necessary, periodically assessing patients’ condition to decide whether to reduce the maintenance dosage.

Clopixol Depot may affect the ability to drive and operate motor vehicles and other mechanisms.

Therefore, caution should be exercised at the beginning of therapy until the patient’s response to treatment has been determined.

Contraindications

Chronic hepatitis;

Severe cardiovascular disease.

Side effects

Possible:

Extrapyramidal disorders;

Tardive dyskinesia;

Malignant neuroleptic syndrome;

Sleepiness;

Dizziness;

Dry mouth;

Impaired accommodation;

Urinary retention;

Constipation;

Tachycardia;

Orthostatic hypotension;

Changes in liver function tests.

Overdose

Symptoms: Possible drowsiness, coma, extrapyramidal disorders, seizures, arterial hypotension, shock, hyper- or hypothermia.

Treatment:If the drug is ingested, the stomach should be flushed as soon as possible, a sorbent is recommended.

The subsequent symptomatic and supportive therapy is carried out.

Measures should be taken to maintain respiratory and cardiovascular activity.

Adrenaline should not be used.

Pregnancy use

Clopixol is not recommended for use in pregnancy and during lactation (breastfeeding).

Similarities